SHR-1314 + Placebo

Phase 3UNKNOWN

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Moderate-to-Severe Plaque Psoriasis

Conditions

Moderate-to-Severe Plaque Psoriasis

Trial Timeline

Apr 25, 2021 → Aug 30, 2023

NCT ID

NCT04839016

About SHR-1314 + Placebo

SHR-1314 + Placebo is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Moderate-to-Severe Plaque Psoriasis. The current trial status is unknown. This product is registered under clinical trial identifier NCT04839016. Target conditions include Moderate-to-Severe Plaque Psoriasis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04839016	Phase 3	UNKNOWN	Apr 25, 2021	Aug 30, 2023	Moderate-to-Severe Plaque Psoriasis
NCT03463187	Phase 1/2	Completed	Dec 15, 2017	Aug 31, 2020	Moderate-to-severe Chronic Plaque Psoriasis

Competing Products

13 competing products in Moderate-to-Severe Plaque Psoriasis

See all competitors

Product	Company	Stage	Hype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacaine	Pacira Biosciences	Approved	80
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + Placebo	Sun Pharmaceutical	Phase 2/3	65
SHR-1314	Jiangsu Hengrui Medicine	Phase 1	33
SHR-1314 + Placebo	Jiangsu Hengrui Medicine	Phase 1/2	41
Indacaterol + Control	Novartis	Phase 3	77
Deucravacitinib	Bristol Myers Squibb	Pre-clinical	22
Dupilumab + Placebo	Sanofi	Phase 3	76
dupilumab	Sanofi	Approved	84
dupilumab	Sanofi	Pre-clinical	22
Ponesimod	Vanda Pharmaceuticals	Phase 3	69
sufentanil sublingual tablet 30 mcg	Talphera	Phase 3	69
Zalviso™ 15 mcg	Talphera	Phase 3	69
sufentanil sublingual 30 mcg tablet	Talphera	Phase 3	69

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved

Remimazolam TosilateApproved

Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved

ImrecoxibApproved

IvarmacitinibApproved